Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Lewis, R. Articles by Zipursky, R. B. Search for Related Content PubMed Citation Articles by Lewis, R. Articles by Zipursky, R. B. Neurotransmitters Schizophrenia Spectrum Disorders PET

Serotonin 5-HT₂ Receptors in Schizophrenia: A PET Study Using [¹⁸F]Setoperone in Neuroleptic-Naive Patients and Normal Subjects

OBJECTIVE: Several postmortem studies have reported a decreased density of serotonin 5-HT₂ receptors in the prefrontal cortex in schizophrenia. The purpose of this study was to investigate this in patients with schizophrenia by means of [¹⁸F]setoperone and positron emission tomography (PET) imaging. METHOD: Thirteen neuroleptic-free patients with schizophrenia, 10 of whom were also neuroleptic-naive, were compared with a group of 26 normal subjects in the same age range. The density of 5-HT₂ receptors was assessed with the use of [¹⁸F]setoperone and PET in standardized cortical regions of interest. RESULTS: Increasing age was associated with similar declines in 5-HT₂ receptors in all cortical regions in the patient group and in the normal comparison group. After control for the effect of age, there was no statistically significant difference between the patients and the comparison subjects in 5-HT₂ receptor density in any of the cortical regions. CONCLUSIONS: This study failed to find the decrease in 5-HT₂ receptors reported in postmortem studies of schizophrenia. The study had the power to detect a decrease of 25% or more in 5-HT₂ receptors, which was anticipated on the basis of the previous postmortem studies. Thus, a primary serotonergic abnormality in schizophrenia, if one exists, is either small or unlikely to be at the level of the 5-HT₂ receptors. This finding does not rule out a therapeutic role for 5-HT₂ antagonists in schizophrenia, but it does suggest that the therapeutic contribution is likely to be an indirect one.

This article has been cited by other articles:

				J. H. Meyer, S. Kapur, B. Eisfeld, G. M. Brown, S. Houle, J. DaSilva, A. A. Wilson, S. Rafi-Tari, H. S. Mayberg, and S. H. Kennedy The Effect of Paroxetine on 5-HT2A Receptors in Depression: An [18F]Setoperone PET Imaging Study Am J Psychiatry, January 1, 2001; 158(1): 78 - 85. [Abstract] [Full Text]

				E. T.C. Ngan, L. N. Yatham, T. J. Ruth, and P. F. Liddle Decreased Serotonin 2A Receptor Densities in Neuroleptic-Naive Patients With Schizophrenia: A PET Study Using [18F]Setoperone Am J Psychiatry, June 1, 2000; 157(6): 1016 - 1018. [Abstract] [Full Text]

				S. Kapur, R. Zipursky, C. Jones, C. S. Shammi, G. Remington, and P. Seeman A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy Arch Gen Psychiatry, June 1, 2000; 57(6): 553 - 559. [Abstract] [Full Text] [PDF]

				S. Kapur, R. B. Zipursky, and G. Remington Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia Am J Psychiatry, February 1, 1999; 156(2): 286 - 293. [Abstract] [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us